Depemokimab is an anti-interleukin-5 agent that can be administered every six months, offering a less frequent dosing alternative.
In a phase 3 study, 629 patients 12 and older participated, including 419 who had previously received depemokimab and 210 who had taken a placebo in an earlier trial.
After 52 weeks of treatment, annualized exacerbation rates were 0.46 for those who had previously used depemokimab and 0.48 for those transitioning from a placebo. Overall, 72% of patients were exacerbation free and 96% did not require hospitalization or emergency department visits.
GSK has submitted depemokimab for FDA approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
